Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025

Stonegate Capital Partners updated its coverage on Incannex Healthcare (IXHL), noting a reduced net loss of $3.97M for the third quarter of fiscal year 2025 compared to $6.03M year-over-year, driven by cost containment and strategic cost-saving initiatives. IXHL's cash position improved to $6.7M due to recent financing and R&D tax incentives; the company will also repurchase outstanding Series A Warrants for ~$24.7M in shares to mitigate dilution and secured $12.5M in private placement funding, with Stonegate's probability-adjusted DCF model estimating a share valuation range of $5.30 to $5.94.

Analysis

Stonegate Capital Partners' updated coverage on Incannex Healthcare Inc. (NASDAQ: IXHL) highlights significant financial improvements and strategic capital management initiatives in its third quarter of fiscal year 2025. The company demonstrated enhanced cost control, with R&D expenses decreasing to $2.74M from $3.28M year-over-year and SG&A expenses falling to $2.27M from $4.14M, contributing to a reduced net loss of $3.97M compared to $6.03M in the prior-year period. This financial discipline, coupled with recent financing and R&D tax incentive payments, increased IXHL's cash and cash equivalents to $6.7M from $2.1M at the end of Q2 2024. Proactive capital management is evident through the securing of $12.5M in at-the-market private placement funding and a plan to issue approximately $24.7M in shares to repurchase all outstanding Series A Warrants, thereby addressing potential dilution from 347.2M underlying shares. Based on these developments, Stonegate's probability-adjusted DCF model estimates a share valuation for IXHL between $5.30 and $5.94, with a midpoint of $5.61.

Key Decisions for Investors

• Investors should consider IXHL's Q3 FY2025 results, particularly the reduced net loss driven by lower R&D and SG&A expenses, as indicative of improved operational efficiency and financial stewardship.
• The company's recent capital management actions, including the $12.5M private placement and the planned share-for-warrant exchange to repurchase Series A Warrants, should be evaluated for their impact on the balance sheet, shareholder dilution, and funding for future development.
• Stonegate Capital Partners' probability-adjusted DCF valuation range of $5.30 to $5.94 provides a specific analytical benchmark that investors can use to assess IXHL's current market price and future potential, contingent on continued execution of its strategic plans.